PerkinElmer, NCDS To Advance Personalized Medicine In China

PerkinElmer, Inc. has announced a new collaboration with the National Center for Drug Screening to advance personalized medicine and drug profiling in China.

AsianScientist (Apr. 22, 2013) – PerkinElmer, Inc. has announced a new collaboration with the National Center for Drug Screening (NCDS) to advance personalized medicine and drug profiling in China.

Through sharing knowledge, expertise and innovative capabilities, the two organizations aim to establish a personalized drug research and development platform that will validate biomarkers for individualized disease treatment for Chinese patients.

Special guests including key governmental leaders, Mr. Jianjun Cheng, CCP Secretary of Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Mr. Weihua Song, Deputy Director of Shanghai Zhangjiang INNOPARK Administrative Committee; Mr. Robert Friel, PerkinElmer’s Chairman and Chief Executive Officer; and Dr. Ming-Wei Wang, Director of NCDS among others, participated in a ceremony earlier this month celebrating the collaboration at the Chinese National Compound Library in Zhangjiang Hi-tech Park, Shanghai.

“It is an honor for PerkinElmer to collaborate with Dr. Wang, who is one of the pioneers in the field of personalized medicine,” Mr. Friel said. “We look forward to working with Dr. Wang, the National Center for Drug Screening, and Chinese scientists to develop a significant personalized drug research and development technology platform which will enable patients to be treated more accurately, safely, and efficiently.”

The program will include sequencing patient samples in order to establish genomic information for drug profiling, including validation of biomarkers for personalized disease treatment and related informatics solutions.

As a part of this program, PerkinElmer and NCDS will first undertake a study on metabolic diseases to validate new diagnostics for the Chinese populations using next generation sequencing technologies. Once optimized, the technology platform will be implemented in testing laboratories and hospitals throughout China.

“For the majority of drugs that are available in China, the respective biomarkers have not yet been fully validated. We are very excited to build this state-of-the-art personalized medicine program with PerkinElmer which will allow us to offer vital insights to improve the quality of healthcare in China,” said Dr. Wang.

——

Source: PerkinElmer.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist